Agilent Technologies, Inc. (A)
Automate Your Wheel Strategy on A
With Tiblio's Option Bot, you can configure your own wheel strategy including A - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol A
- Rev/Share 22.9228
- Book/Share 21.1474
- PB 5.2612
- Debt/Equity 0.558
- CurrentRatio 2.1974
- ROIC 0.1247
- MktCap 31720559780.0
- FreeCF/Share 4.6035
- PFCF 24.1773
- PE 25.1859
- Debt/Assets 0.2823
- DivYield 0.0087
- ROE 0.2095
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | A | Barclays | Underweight | Equal Weight | $135 | $145 | Feb. 10, 2025 |
| Initiation | A | Wells Fargo | -- | Overweight | -- | $157 | Aug. 28, 2024 |
News
Curious about Agilent (A) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended April 2025.
Read More
Pascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors, effective May 21, 2025. Soriot and Gawlik Brown bring decades of global leadership experience across the pharmaceutical, biotechnology, and health-care sectors, with proven track records in strategy, innovation, operations, and finance. Pascal Soriot has led Astr.
Read More
Will Agilent (A) Beat Estimates Again in Its Next Earnings Report?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Positive
City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures.
Read More
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today
Published: April 03, 2025 by: Seeking Alpha
Sentiment: Positive
Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data shows inflation is falling, contradicting consumer fears and demonstrating that stagflation panic may be premature.
Read More
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
Published: March 24, 2025 by: Business Wire
Sentiment: Neutral
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a.
Read More
CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025
Published: March 20, 2025 by: Business Wire
Sentiment: Neutral
SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will.
Read More
Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Read More
Agilent to Participate in TD Cowen Health Care Conference
Published: February 27, 2025 by: Business Wire
Sentiment: Neutral
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference at 9:50-10:20 a.m. Eastern on Tuesday, March 4, 2025, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a globa.
Read More
Agilent Technologies, Inc. (A) Q1 2025 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Agilent Technologies, Inc. (NYSE:A ) Q1 2025 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Parmeet Ahuja - Vice President of Investor Relations Padraig McDonnell - President and Chief Executive Officer Robert W. McMahon - Senior Vice President and Chief Financial Officer Simon May - President of Life Sciences and Diagnostics Markets Group Angelica Riemann - President of Agilent CrossLab Group Mike Zhang - President of Applied Markets Group Conference Call Participants Rachel Vatnsdal - J.P.
Read More
Agilent (A) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended January 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Agilent lowers annual revenue forecast on soft demand for medical equipment
Published: February 26, 2025 by: Reuters
Sentiment: Negative
Medical equipment maker Agilent lowered its annual revenue forecast on Wednesday, as it expects soft demand for its medical tools and equipment from smaller biotech companies.
Read More
Agilent Reports First-Quarter Fiscal Year 2025 Financial Results
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024. First-quarter GAAP net income was $318 million, or $1.11 per share. This compares with $348 million, or $1.18 per share, in the first quarter of fiscal year 2024. Non-GAAP(2) net income was $377 million, or $1.31 per share during the quarter, com.
Read More
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.
Read More
About Agilent Technologies, Inc. (A)
- IPO Date 1999-11-18
- Website https://www.agilent.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Padraig McDonnell
- Employees 17900